Aesthetic technologies are expanding ophthalmic practice into a broader sphere of patient care. AAO 2025 emphasized that ...
Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving ...
Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving ...
Optogenetics offers mutation-independent vision restoration for IRDs, with promising early-phase results in retinitis ...
AAO 2025 revealed that true-color widefield imaging, AI-powered home OCT, and refined FAERS analyses are collectively transforming retinal diagnostics into a more precise, continuous, and safety-aware ...
Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific ...
Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...
Foundation Fighting Blindness has granted public access to de-identified 4-year data from individuals participating in RUSH2A ...
The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...
Precise Bio has successfully treated a patient with PB-001, the company’s 3D-bio-printed corneal implant, at Rambam Medical ...
The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...
Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する